Table 3 FDA-approved ROS1 TKI and NTRK TKI
From: Emerging therapeutic agents for advanced non-small cell lung cancer
Drug | Month/year | Indication | Comments |
|---|---|---|---|
Crizotinib | March/2016 | Metastatic ROS1 +NSCLC | Â |
Larotrectinib | November/2018 | Advanced or metastatic NTRK gene fusion Solid tumors, no acquired resistance mutation, and have no satisfactory alternative treatments available | Adult and pediatric patients |
Entrectinib | August/2019 | Adult metastatic ROS1 +NSCLC, adult and pediatric patients 12 years of age and older with advanced or metastatic NTRK gene fusion solid tumors, no acquired resistance mutation, have progressed following treatment or have no satisfactory alternative therapy, available |  |